Search clinical trials for: MORAb-066

Total 834 results

Morphotek
SCRI Development Innovations, LLC

Completed

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Adenocarcinoma | Breast Cancer | Carcinoma, Non-Small-Cell Lung | Colorectal Cancer | Pancreatic Cancer

United States
Morphotek

Completed

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Pancreatic Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer

United States
AbbVie

No longer available

Expanded Access to Risankizumab

Crohn's Disease | Ulcerative Colitis (UC)
Eisai Co., Ltd.

Completed

A Study of MORAb-009 in Patients With Solid Tumor

Cancer | Mesothelin-positive

Japan
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
AbbVie

Completed

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Psoriasis

Japan
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) (LIMMITLESS)

Psoriasis

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Sweden, Taiwan
AbbVie

Completed

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis

United States, Australia, Canada, Japan, Puerto Rico
AbbVie

Completed

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Psoriatic Arthritis
Eisai Co., Ltd.

Completed

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)

Solid Tumor

Japan
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

Japan
AbbVie

Completed

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

Healthy Volunteers

United States
AbbVie
Boehringer Ingelheim

Completed

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
AbbVie

Completed

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Psoriasis

Russian Federation
AbbVie

Completed

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Morphotek

Terminated

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Metastatic Colorectal Cancer | Colorectal Cancer

United States
Morphotek

Completed

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Mesothelioma

United States
National Cancer Institute (NCI)

Terminated

Amatuximab for High Mesothelin Cancers

Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Mesothelioma | Carcinoma, Pancreatic Ductal

United States
AbbVie
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Asthma

United States, Korea, Republic of, Belgium, Taiwan, Canada, Germany, United Kingdom, France, Netherlands, Poland
Biocad

Completed

Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers

Healthy

Russian Federation
AbbVie

Completed

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
AlaMab Therapeutics (Shanghai) Inc.

Recruiting

Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury

Acute Spinal Cord Injury

China
Morphotek

Completed

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Epithelial Ovarian Cancer

United States
AbbVie

Active, not recruiting

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1)

Psoriasis

United States, Canada, Germany, Japan, Poland, Spain, United Kingdom
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
Vaxon Biotech

Completed

Safety Study of Vx006 Vaccine in Solid Tumor Patients

Solid Tumor

Greece
Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
Morphotek

Withdrawn

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Resectable, Non-functioning Pituitary Adenoma

United States
Eisai Co., Ltd.

Completed

A Study of MORAb-003 in Patients With Solid Tumor

Neoplasms | Solid Tumor

Japan
VA Office of Research and Development

Completed

Pilot Study Testing a Web-Based Moral Elevation Intervention for Veterans With PTSD and Moral Injury

Posttraumatic Stress Disorder | Moral Injury

United States
Terumo Europe N.V.

Recruiting

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)

Hepatocellular Carcinoma

Germany
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
Morphotek
National Cancer Institute (NCI); Children's Oncology Group

Completed

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
Forest Laboratories
University of Florida

Terminated

A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain (EUR-1066)

Chronic Pancreatitis

United States
AbbVie

Completed

A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

Healthy Volunteers

United States
AbbVie

Completed

A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants

Healthy Volunteers

United States
Morphotek

Terminated

An Open Label Extension Study of the Efficacy of MORAb-003

Epithelial Ovarian Cancer

United States, Germany
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Effect of Implementation of a Moral Case Delibration Meetings on the Prevalence of Burn-out Syndrome in the ICU (MCDIC)

Burnout, Professional | Caregiver Exhaustion

Netherlands
Unity Health Toronto
McMaster University; University of Toronto; Ryerson University; University of Ontario...

Completed

Digital Interventions for Detection and Reduction of Moral Distress (VR)

Distress, Emotional | Moral Injury

Canada
Wave Life Sciences Ltd.

Recruiting

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) (RestorAATion-1)

Alpha-1 Antitrypsin Deficiency

United Kingdom
Nitto BioPharma, Inc.

Active, not recruiting

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer

United States
NCIC Clinical Trials Group
Cascadian Therapeutics Inc.

Completed

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Glioblastoma

Canada
NCIC Clinical Trials Group
Oncothyreon Canada Inc.

Completed

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

Canada
Shanghai Antengene Corporation Limited

Terminated

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors (REACH)

Advanced Solid Tumors

China
Cascadian Therapeutics Inc.

Completed

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

Healthy Volunteer

United States
Pfizer

Completed

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

Diabetes Mellitus, Type 2

United States
Argos Therapeutics

Completed

A Single-Patient Study Using AGS 006

Pancreatic Cancer

United States

3

Subscribe